Cargando…

Metalloproteinases and Tissue Inhibitors in Generalized Myasthenia Gravis. A Preliminary Study

Introduction: Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) have recently been proposed as promising biomarkers in different immune-mediated disorders. We evaluated the plasma levels of MMP-9 and MMP-2 and their tissue inhibitors TIMP-1 and TIMP-2 in a patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Stefano, Vincenzo, Tubiolo, Chiara, Gagliardo, Andrea, Presti, Rosalia Lo, Montana, Maria, Todisco, Massimiliano, Lupica, Antonino, Caimi, Gregorio, Tassorelli, Cristina, Fierro, Brigida, Brighina, Filippo, Cosentino, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688860/
https://www.ncbi.nlm.nih.gov/pubmed/36358365
http://dx.doi.org/10.3390/brainsci12111439
_version_ 1784836376257101824
author Di Stefano, Vincenzo
Tubiolo, Chiara
Gagliardo, Andrea
Presti, Rosalia Lo
Montana, Maria
Todisco, Massimiliano
Lupica, Antonino
Caimi, Gregorio
Tassorelli, Cristina
Fierro, Brigida
Brighina, Filippo
Cosentino, Giuseppe
author_facet Di Stefano, Vincenzo
Tubiolo, Chiara
Gagliardo, Andrea
Presti, Rosalia Lo
Montana, Maria
Todisco, Massimiliano
Lupica, Antonino
Caimi, Gregorio
Tassorelli, Cristina
Fierro, Brigida
Brighina, Filippo
Cosentino, Giuseppe
author_sort Di Stefano, Vincenzo
collection PubMed
description Introduction: Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) have recently been proposed as promising biomarkers in different immune-mediated disorders. We evaluated the plasma levels of MMP-9 and MMP-2 and their tissue inhibitors TIMP-1 and TIMP-2 in a patients’ cohort with generalized myasthenia gravis (MG). Methods: Plasma concentrations of MMP-9, MMP-2, TIMP-1 and TIMP-2 were evaluated in 14 patients with generalized MG and 13 age- and sex-matched healthy controls. The severity of disease was assessed by the modified Osserman classification. Results: Compared to the healthy subjects, MG patients had increased plasma concentrations of MMP-9, but reduced plasma levels of MMP-2 and TIMP-1. MG patients also showed a positive correlation between MMP-2 concentrations and disease severity. An increase in MMP-9 levels and MMP-9/TIMP-1 ratio and a decrease in MMP-2 levels and MMP-2/TIMP-2 ratio were detected in patients with generalized MG. Higher levels of MMP-2 correlated with greater disease severity. Discussion: Our preliminary findings suggest that MMPs and TIMPs could play a role in the pathogenesis of MG and might be associated with the risk of clinical deterioration.
format Online
Article
Text
id pubmed-9688860
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96888602022-11-25 Metalloproteinases and Tissue Inhibitors in Generalized Myasthenia Gravis. A Preliminary Study Di Stefano, Vincenzo Tubiolo, Chiara Gagliardo, Andrea Presti, Rosalia Lo Montana, Maria Todisco, Massimiliano Lupica, Antonino Caimi, Gregorio Tassorelli, Cristina Fierro, Brigida Brighina, Filippo Cosentino, Giuseppe Brain Sci Article Introduction: Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) have recently been proposed as promising biomarkers in different immune-mediated disorders. We evaluated the plasma levels of MMP-9 and MMP-2 and their tissue inhibitors TIMP-1 and TIMP-2 in a patients’ cohort with generalized myasthenia gravis (MG). Methods: Plasma concentrations of MMP-9, MMP-2, TIMP-1 and TIMP-2 were evaluated in 14 patients with generalized MG and 13 age- and sex-matched healthy controls. The severity of disease was assessed by the modified Osserman classification. Results: Compared to the healthy subjects, MG patients had increased plasma concentrations of MMP-9, but reduced plasma levels of MMP-2 and TIMP-1. MG patients also showed a positive correlation between MMP-2 concentrations and disease severity. An increase in MMP-9 levels and MMP-9/TIMP-1 ratio and a decrease in MMP-2 levels and MMP-2/TIMP-2 ratio were detected in patients with generalized MG. Higher levels of MMP-2 correlated with greater disease severity. Discussion: Our preliminary findings suggest that MMPs and TIMPs could play a role in the pathogenesis of MG and might be associated with the risk of clinical deterioration. MDPI 2022-10-26 /pmc/articles/PMC9688860/ /pubmed/36358365 http://dx.doi.org/10.3390/brainsci12111439 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Di Stefano, Vincenzo
Tubiolo, Chiara
Gagliardo, Andrea
Presti, Rosalia Lo
Montana, Maria
Todisco, Massimiliano
Lupica, Antonino
Caimi, Gregorio
Tassorelli, Cristina
Fierro, Brigida
Brighina, Filippo
Cosentino, Giuseppe
Metalloproteinases and Tissue Inhibitors in Generalized Myasthenia Gravis. A Preliminary Study
title Metalloproteinases and Tissue Inhibitors in Generalized Myasthenia Gravis. A Preliminary Study
title_full Metalloproteinases and Tissue Inhibitors in Generalized Myasthenia Gravis. A Preliminary Study
title_fullStr Metalloproteinases and Tissue Inhibitors in Generalized Myasthenia Gravis. A Preliminary Study
title_full_unstemmed Metalloproteinases and Tissue Inhibitors in Generalized Myasthenia Gravis. A Preliminary Study
title_short Metalloproteinases and Tissue Inhibitors in Generalized Myasthenia Gravis. A Preliminary Study
title_sort metalloproteinases and tissue inhibitors in generalized myasthenia gravis. a preliminary study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688860/
https://www.ncbi.nlm.nih.gov/pubmed/36358365
http://dx.doi.org/10.3390/brainsci12111439
work_keys_str_mv AT distefanovincenzo metalloproteinasesandtissueinhibitorsingeneralizedmyastheniagravisapreliminarystudy
AT tubiolochiara metalloproteinasesandtissueinhibitorsingeneralizedmyastheniagravisapreliminarystudy
AT gagliardoandrea metalloproteinasesandtissueinhibitorsingeneralizedmyastheniagravisapreliminarystudy
AT prestirosalialo metalloproteinasesandtissueinhibitorsingeneralizedmyastheniagravisapreliminarystudy
AT montanamaria metalloproteinasesandtissueinhibitorsingeneralizedmyastheniagravisapreliminarystudy
AT todiscomassimiliano metalloproteinasesandtissueinhibitorsingeneralizedmyastheniagravisapreliminarystudy
AT lupicaantonino metalloproteinasesandtissueinhibitorsingeneralizedmyastheniagravisapreliminarystudy
AT caimigregorio metalloproteinasesandtissueinhibitorsingeneralizedmyastheniagravisapreliminarystudy
AT tassorellicristina metalloproteinasesandtissueinhibitorsingeneralizedmyastheniagravisapreliminarystudy
AT fierrobrigida metalloproteinasesandtissueinhibitorsingeneralizedmyastheniagravisapreliminarystudy
AT brighinafilippo metalloproteinasesandtissueinhibitorsingeneralizedmyastheniagravisapreliminarystudy
AT cosentinogiuseppe metalloproteinasesandtissueinhibitorsingeneralizedmyastheniagravisapreliminarystudy